<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/224747-a-pharmaceutical-composition-comprising-raloxifene-a-surfactant-and-a-watersoluble-diluent by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 00:59:17 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 224747:A PHARMACEUTICAL COMPOSITION COMPRISING RALOXIFENE, A SURFACTANT AND A WATERSOLUBLE DILUENT.</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">A PHARMACEUTICAL COMPOSITION COMPRISING RALOXIFENE, A SURFACTANT AND A WATERSOLUBLE DILUENT.</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>This invention provides orally administerable pharmaceutical formulations comprising raloxifene, its ethers or esters, or a pharmaceutically-acceptable salt thereof, in combination with a hydrophilic carrier composition.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>FIELD OF THE INVENTION<br>
The present invention relates to an orally administrable<br>
pharmaceutical formulation comprising raloxifene, its ethers or<br>
esters, or a pharmaceutically acceptable salt thereof, in<br>
combination with a hydrophilic carrier composition.<br>
BACKGROUND OF THE PRIOR ART<br>
Certain benzothiophenes of the formula<br><br>
wherein R and R1 are independently hydrogen, COR2, or R3;<br>
R1 is hydrogen, C1-C14 alkyl, C1-C9 chloroalkyl, C1-C3<br>
fluorcalkyl, C5-C7 cycloalkyl, C1-C4 alkoxy, phenyl, or phenyl mono-<br>
cr disubstituted with C1-C4 alkyl, C1-C4 alkoxy, hydroxy, nitro,<br>
chlorc, fluoro, cr trichloro or fluoro) methyl;<br>
R3 is C1-C3 alkyl, C5-C7 cycloalkyl, or benzyl; or<br>
a pharmaceutically-acceptable salt thereof;<br>
are nonsteriodal antiestrogens and antiandrogens. These<br>
compounds are useful in the treatment, of mammary and prostatic<br>
tumors, and in the treatment of mammary and prostatic fibrocystic<br>
disease. The formula I compounds are described in U.S. Patent No.<br>
4,418,068 (issued November 29, 1983) . This patent described the<br>
preparation of these compounds, as well as their use for<br>
antiestrogen and antiandrogen therapy. The preparation of<br>
pharmaceutical compositions for antiestrogenic and antiandrogenic<br>
therapy was also described.<br>
Raloxifene, which is 6-hydroxy-2- (4-hydroxyphenyl)-3 - [4- (2 -<br>
piperidinoethoxy)benzoyl]benzo [b]thiophene, is a particulary useful<br>
compound from this series of benzothiophenes. Raloxifene<br>
competitively inhibits estrogen action in a number of in vitro and<br>
in vivo models. Black,- Jones, and Falcone, Life Sci., 32, 1031-1036<br>
(1983); Knecht, Tsai-Morris, and Catt, Endocrinology, 116, 1771-1777<br>
(1985); • and Sirnard and Labrie, Mol. Cell. Endocrinology, 39, 141-144<br>
(1985). This compound also displays some estrogen-like actions in<br>
addition to its estrogen-antagonistic effects. Ortmann, Emons,<br>
Knuppen, and Catt, Endocrinology, 123, 962-963 (1988). A recent<br>
report suggests that raloxifene is useful in the treatment of<br>
osteoporosis in postmenopausal women. Turner, Sato, and Bryant,<br>
Journal of Clinical Investigation (In Press).<br>
The formula I compounds may be administered as<br>
pharmaceutically-acceptable salts. A particularly useful<br>
pharmaceutically-acceptable salt of raloxifene is the hydrochloride<br>
salt. This salt form is easily prepared by the addition of hydrogen<br>
chloride to a solution of raloxifene in an organic solvent, such as<br>
tetrahydrofuran or methanol. Aqueous solubility of raloxifene<br>
hydrochloride, however, is far below what would be expected for an<br>
organic hydrochloride salt containing two phenolic hydroxyl groups.<br>
This poor solubility has somewhat limited the bioavailability of<br>
this preferred salt form. Another significant barrier to optimum and<br>
consistent absorption of raloxifene hydrochloride is its<br>
hydrophobicity.<br>
STATEMENT OF THE INVENTION<br>
Accordingly, the present invention relates to a pharmaceutical<br>
composition comprising raloxifene, its esters or ethers, in<br>
combination with a surfactant and a water-soluble diluent and<br>
optionally a lubricant, disintegrant, hydrophilic binder and a film<br>
coating.<br>
SUMMARY OF THE INVENTION<br>
To overcome the limited bioavailability, the present invention<br>
provides orally administerable pharmaceutical formulations<br>
comprising raloxifene, its esters or ethers, or a pharmaceutically-<br>
acceptable salt thereof, in combination with a hydrophilic carrier<br>
composition, such formulations having increased solubility in<br>
aqueous media. More particularly, the present invention provides an<br>
orally administerable pharmaceutical formulation comprising<br>
raloxifene, its esters or ethers, or a pharmaceutically-acceptable<br>
salt thereof, in combination with a surfactant, a water-soluble<br>
diluent, and optionally a hydrophilic binder. The present invention<br>
also provides pharmaceutical formulations further comprising a<br>
lubricant and a disintegrant.<br>
DETAILED DESCRIPTION<br>
The present invention provides orally administerable<br>
pharmaceutical formulations comprising raloxifene, its esters or<br>
ethers, or a pharmaceutically-acceptable salt thereof, in<br>
combination with a surfactant, a water-soluble diluent, and<br>
optionally a hydrophilic binder. Raloxifene, its esters, and its<br>
ethers are represented by the following formula:<br>
wherein R and R1 are independently hydrogen, COR2, or R2;<br>
R2 is hydrogen, C1-C14, alkyl, C1-C3 chloroalkyl, C1—C3<br>
fluoroalkyl, C5-C7 cycloalkyl, C1-C4 alkoxy, phenyl, or phenyl mono-<br>
or disubstituted with C2-C4 alkyl, C1-C4<br>
alkoxy, hydroxy, nitro, chloro, fluoro, or tri(chloro or<br>
fluoro)methyl;<br>
R3 is C1-C4 alkyl, C5-C7 cycloalkyl, or benzyl.<br>
Raloxifene is the compound wherein R and R1 are hydrogen.<br>
The preparation of this compound is described in U.S.<br>
Patent No. 4,418,068, which is incorporated herein by<br>
reference. A pharmaceutical chemist will readily recognize<br>
that this compound can be effectively administered as an<br>
ether or ester, formed on either one or both of the<br>
phenolic hydroxyl groups. The preparation of these esters<br>
and ethers is also described in U.S. Patent No. 4,418,068.<br>
The general chemical terms used in the above formula<br>
have their usual meanings. The term "C1-C14 alkyl"<br>
represents a straight or branched alkyl chain having from<br>
one to 14 carbon atoms. Typical C1-C14 alkyl groups<br>
include methyl, ethyl, n-propyl, isopropyl, n-butyl,<br>
isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, n-hexyl,<br>
2-methylpentyl, n-octyl, decyl, 2-methyldecyl, 2,2-<br>
dimethyldecyl, undecyl, dodecyl, and the like. The term<br>
"C1-C14 alkyl" includes within it the term "C1-C4 alkyl".<br>
Typical C1-C4 alkyl groups include methyl, ethyl, n-propyl,<br>
isopropyl, n-butyl, isobutyl, sec-butyl, and t-butyl.<br>
The terms "C1-C3 chloroalkyl" and "C1-C3 fluoroalkyl"<br>
represent methyl, ethyl, propyl, and isopropyl substituted<br>
to any degree with chlorine or florine atoms, from one atom<br>
to full substitution. Typical C1-C3 chloroalkyl groups<br>
include chloromethyl, dichloromethyl, trichloromethyl, 2-<br>
chlorethyl, 2,2-dichloroethyl, 2,2,2-trichloroethyl, 1,2-<br>
dichloroethyl, 1,1,2,2-tetrachloroethyl, 1,2,2,2-<br>
tetrachloroethyl, pentachlorethyl, 3-chloropropyl, 2-<br>
chloropropyl, 3,3-dichloropropyl, 2,3-dichloropropyl, 2,2-<br>
dichloropropyl, 3,3,3-trichloropropyl, and 2,2,3,3,3-<br><br>
pentachloropropvl. Typical C1-C3 fluoroalkyl groups<br>
include fluoromethyl, difluoromethyl, trifluoromethyl, 2-<br>
fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 1,2-<br>
difluoroethyl, 1,1,2,2-tetrafluoroethyl, 1,2,2,2-<br>
tetrafluoroethyl, pentafluoroethyl, 3-fluoropropyl, 2-<br>
fluoropropyl, 3,3-difluoropropyl, 2,3-difluoropropyl, 2,2-<br>
difluoropropyl, 3,3,3-trifluoropropyl, and 2,2,3,3,3-<br>
pentafluoropropyl.<br>
The term "C5-C7 cycloalkyl" represents cyclic<br>
hydrocarbon groups containing from five to seven carbon<br>
atoms. The C5-C7 cycloalkyl groups are cyclopentyl,<br>
cyclohexyl, and cycloheptyl.<br>
The term "C1-C4 alkoxy" represents groups such as<br>
methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy,<br>
and the like groups.<br>
The term "pharmaceutically-acceptable salt" represents<br>
salt forms of raloxifene, its esters, or its ethers that<br>
are physiologically suitable for pharmaceutical use. The<br>
pharmaceutically-acceptable salts can exist in conjunction<br>
with raioxifene, its esters, or its ethers as acid addition<br>
primary, secondary, tertiary, or quaternary ammonium,<br>
alkali metal, or alkaline earth metal salts. Generally,<br>
the acid addition salts are prepared by the reaction of an<br>
acid with a compound of formula I, wherein R, R1, R2, and<br>
R3, are as defined previously. The alkali metal and<br>
alkaline earth metal salts are generally prepared by the<br>
reaction of the metal hydroxide of the desired metal salt<br>
with a compound of formula I, wherein at least one of R and<br>
R1 is hydrogen.<br>
Acids commonly employed to form such acid addition<br>
salts include organic acids such as hydrochloric,<br>
hydrobromic, hydriodic, sulfuric, and phosphoric acid, as<br>
well as organic acids such as toluenesulfonic,<br>
methanesulfonic, oxalic, para-bromophenylsulfonic,<br>
carbonic, succinic, citric, benzoic, and acetic acid, and<br>
related inorganic and organic acids. Such<br>
pharmaceutically-acceptable salts thus include sulfate,<br>
pyrosulfate, bisulfate, sulfite, bisulfite, phosphate,<br>
ammonium, monohydrogen phosphate, dihydrogen phosphate,<br>
meta-phosphate, pyrophosphate, chloride, bromide, iodide,<br>
acetate, propionate, decanoate, caprolate, acrylate,<br>
formate, isobutyrate, caprate, heptanoate, propionate,<br>
oxalate, malonate, succinate, subarate, sebacate, fumarate,<br>
hippurate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate,<br>
benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate,<br>
hydroxybenzoate, methoxybenzoate, phthalate, sulfonate,<br>
xylenesulfonate, phenylacetate, phenylpropionate,<br>
phenylbutyrate, citrate, lactate, a-hydroxybutyrate,<br>
glycolate, tartrate, methanesulfonate, propanesulfonate,<br>
naphthalene-1-sulfonate, naphthalene-2-sulfonate,<br>
mandelate, ammonium, magnesium, tetramethylammonium,<br>
potassium, trimethylammonium, sodium, methylammonium,<br>
calcium, and the like salts.<br>
The term "hydrophilic binder" represents binders<br>
commonly used in the formulation of Pharmaceuticals, such<br>
as polyvinyipyrrolidone, polyethylene glycol, sucrose,<br>
dextrose, corn syrup, polysaccharides (including acacia,<br>
tragacanth, guar, and alginates), gelatin, and cellulose<br>
derivatives (including hydroxypropyl methylcellulose,<br>
hydroxypropyl cellulose, and sodium<br>
carboxymethylcellulose).<br>
The term "surfactant", as used herein, represents<br>
ionic and nonionic surfactants or wetting agents commonly<br>
used in the formulation of Pharmaceuticals, such as<br>
ethoxylated castor oil, polyglycolyzed glycerides,<br>
acetylated monoglycerides, sorbitan fatty acid esters,<br><br>
poloxamers, polyoxyethylene sorbitan fatty acid esters,<br>
polyoxyethylene derivatives, monoglycerides or ethoxylated<br>
derivatives thereof, diglycerides or polyoxyethylene<br>
derivatives thereof, sodium docusate, sodium laurylsulfate,<br>
cholic acid or derivatives thereof, lecithins, and<br>
phospholipids.<br>
The term "water-soluble diluent" represents compounds<br>
typically used in the formulation of Pharmaceuticals, such<br>
as sugars (including lactose, sucrose, and dextrose),<br>
polysaccharides (including dextrates and maltodextrin),<br>
polyols (including mannitol, xylitol, and sorbitol), and<br>
cyclodextrins.<br>
The term "disintegrant" represents compounds such as<br>
starches, clays, celluloses, alginates, gums, cross-linked<br>
polymers (such as cross-linked polyvinylpyrrolidone and<br>
cross-linked sodium carboxymethylcellulose), sodium starch<br>
glycolate, low-substituted hydroxypropyl cellulose, and soy<br>
polysaccharides. Preferably the disintegrant is a cross-<br>
linked polymer, more preferably cross-linked<br>
polyvinylpyrrolidone.<br>
The term "lubricant" represents compounds frequently<br>
used as lubricants or glidants in the preparation of<br>
phax~maceuticals, such as talc, magnesium stearate, calcium<br>
stearate, stearic acid, colloidal silicon dioxide,<br>
magnesium carbonate, magnesium oxide, calcium silicate,<br>
microcrystalline cellulose, starches, mineral oil, waxes,<br>
glyceryl behenate, polyethylene glycol, sodium benzoate,<br>
sodium acetate, sodium chloride, sodium laurylsulfate,<br>
sodium stearyl fumarate, and hydrogenated vegetable oils.<br>
Preferably the lubricant is magnesium stearate or stearic<br>
acid, more preferably magnesium stearate.<br>
While all of the formulations of the present invention<br>
have increased solubility in aqueous media and, therefore,<br>
greater bioavailability would be expected, certain<br>
formulations are preferred. Preferably, the surfactant is<br>
an anionic or nonionic surfactant. Representative<br>
surfactants from this preferred group include sodium<br>
laurylsulfate, sodium docusate, ethoxylated castor oil,<br>
polyglycolyzed glycerides, acetylated monoglycerides,<br>
sorbitan fatty acid esters, poloxamers, polyoxyethylene<br>
sorbitan fatty acid esters, polyoxyethylene derivatives,<br>
monoglycerides or ethoxylated derivatives thereof, and<br>
diglycerides or polyoxyethylene derivatives thereof.<br>
Preferably, the water-soluble diluent is a sugar or polyol.<br>
When a hydrophilic binder is present, preferably the binder<br>
is sucrose, dextrose, corn syrup, gelatin, a cellulose<br>
derivative, or polyvinylpyrrolidone.<br>
Certain formulations of the present invention are more<br>
preferred. More preferably, the surfactant is a nonionic<br>
surfactant, such as ethoxylated castor oil, polyglycolyzed<br>
glycerides, acetylated monoglycerides, sorbitan fatty acid<br>
esters, poloxamers, polyoxyethylene sorbitan fatty acid<br>
esters, polyoxyethylene derivatives, monoglycerides or<br>
echoxylated derivatives thereof, and diglycerides or<br>
polyoxyethylene derivatives thereof. More preferably, the<br>
water-soluble diluent is a sugar, such as lactose, sucrose,<br>
and dextrose. More preferably, the hydrophilic binder is a<br>
cellulose derivative or polyvinylpyrrolidone.<br>
Certain formulations of the present invention are most<br>
preferred. Most preferably, the surfactant is a<br>
polyoxyethylene sorbitan fatty acid ester, such as<br>
polysorbate 80. Most preferably, the water-soluble diluent<br>
is lactose. Most preferably the hydrophilic binder, when<br>
present, is polyvinylpyrrolidone.<br>
The orally administerable compositions of the present<br>
invention are prepared and administered according to<br>
methods well known in pharmaceutical chemistry. See<br>
Remington's Pharmaceutical Sciences, 17th ed. (A. Osol<br>
ed., 1985). For example, the compositions of the present<br>
invention may be adminstered by means of solid dosage forms<br>
such as tablets and capsules. Preferably, the compositions<br>
are formulated as tablets. These tablets are prepared by<br>
wet granulation, by dry granulation, or by direct<br>
compression.<br>
Tablets for this invention are prepared utilizing<br>
conventional tabletting techniques. A general method of<br>
manufacture involves blending raloxifene, its ester, ether,<br>
or a salt thereof, the water-soluble diluent, and<br>
optionally a portion of a disintegrant. This blend is then<br>
granulated with a solution of the hydrophilic binder and<br>
surfactant in water and/or organic solvent, such as<br>
methanol, ethanol, isopropanol, methylene chloride, and<br>
acetone, and milled if necessary. The granules are dried<br>
and reduced to a suitable size. Any other ingredients,<br>
such as lubricants, (e.g. magnesium stearate) and<br>
additional disintegrant, are added to the granules and<br>
mixed. This mixture is then compressed into a suitable<br>
size and shape using conventional tabletting machines such<br>
as a rotary tablet press. The tablets may be film coated<br>
by techniques well known in the art.<br>
Capsules for this invention are prepared utilizing<br>
conventional encapsulating methods. A general method of<br>
manufacture involves blending raloxifene, its ester, ether,<br>
or salt thereof, the water-soluble diluent, and optionally<br>
a portion of a disintegrant. This blend is then granulated<br>
with a solution of the hydrophilic binder and surfactant in<br>
water and/or organic solvent, and milled if necessary. The<br>
granules are dried and reduced to a suitable size. Any<br>
other ingredients, such as a lubricant (e.g. colloidal<br>
silicon dioxide) are added to the granules and mixed. The<br>
resulting mixture is then filled into a suitable size hard-<br>
shell gelatin capsule using conventional capsule-filling<br>
machines.<br>
The following formulation examples are illustrative<br>
only and are not intended to limit the scope of the<br>
invention in any way. Tablets may be prepared using the<br>
ingredients and procedures as described below:<br>
The mixture of raloxifene HCl, lactose, and a portion<br>
of the cross-linked polyvinylpyrrolidone is granulated with<br>
an aqueous solution of the polyvinylpyrrolidone and<br>
polysorbate 80. The granules are dried, reduced to a<br>
suitable size, and mixed with stearic acid, magnesium<br>
stearate, and remaining cross-linked polyvinylpyrrolidone.<br>
The mixture is compressed into individual tablets yielding<br>
a tablet weight of 525 mg.<br>
The mixture of raloxifene HCl, lactose anhydrous,<br>
dextrose, and a portion of the cross-linked<br>
polyvinylpyrrolidone is granulated with an alcoholic<br>
solution of polyvinylpyrrolidone and polysorbate 80. The<br>
granules are dried, reduced to a suitable size, and mixed<br>
with magnesium stearate, stearic acid, and remaining cross-<br>
linked polyvinylpyrrolidone. The mixture is compressed<br>
into individual tablets yielding a tablet weight of 525 mg.<br><br>
The mixture of raloxifene HCl, dextrose, and cross-<br>
linked sodium carboxymethylcellulose is granulated with an<br>
aqueous solution of hydroxypropyl cellulose and sodium<br>
laurylsulfate. The granules are dried, reduced to a<br>
suitable size, and mixed with magnesium stearate. The<br>
mixture is compressed into individual tablets yielding a<br>
tablet weight of 400 mg.<br><br>
The mixture of raloxifene HCl, lactose anhydrous,<br>
spray-dried hydrous lactose, and a portion of the cross-<br>
linked polyvinylpyrrolidone is granulated with an aqueous<br>
solution of polyvinylpyrrolidone and polysorbate 80. The<br>
granules are dried, reduced to a suitable size, and mixed<br>
with magnesium stearate and remaining cross-linked<br>
polyvinylpyrrolidone. The mixture is compressed into<br>
individual tablets yielding a tablet weight of 240 mg.<br><br>
The mixture of raloxifene HCl, anhydrous lactose, and<br>
cross-linked sodium carboxymethylcellulose is granulated<br>
with an aqueous solution of poloxamer and hydroxypropyl<br>
cellulose. The granules are dried, reduced to a suitable<br>
size, and mixed with stearic acid and magnesium stearate.<br>
The mixture is then compressed into individual tablets<br>
yielding a tablet weight of 240 mg.<br><br>
The mixture of raloxifene HCl, lactose, dextrose, and<br>
cross-linked polyvinylpyrrolidone is granulated with an<br>
aqueous solution of hydroxypropyl methylcellulose and<br>
sodium laurylsulfate. The granules are dried, reduced to a<br>
suitable size, and mixed with the stearic acid. The<br>
mixture is then compressed into individual tablets yielding<br>
a tablet weight of 240 mg.<br><br>
The mixture of raloxifene HCl, lactose anhydrous, and<br>
cross-linked polyvinylpyrrolidone is granulated with an<br>
aqueous solution of polyvinylpyrrolidone and polysorbate<br>
80. The granules are dried, reduced to a suitable size,<br>
and mixed with magnesium stearate. The mixture is then<br>
compressed into individual tablets yielding a tablet weight<br>
of 240 mg.<br><br>
The mixture of raloxifene HCl, lactose anhydrous,<br>
spray-dried hydrous lactose, and a portion of the cross-<br>
linked polyvinylpyrrolidone is granulated with an aqueous<br>
solution of polyvinylpyrrolidone and polysorbate 80. The<br>
granules are dried, reduced to a suitable size, and mixed<br>
with magnesium stearate and remaining cross-linked<br>
polyvinylpyrrolidone. The mixture is then compressed into<br>
individual tablets yielding a tablet weight of 240 mg.<br><br>
The mixture of raloxifene HC1, mannitol, dextrose, and<br>
sodium starch glycolate is granulated with an aqueous<br>
solution of polysorbate SO and hydroxypropyl<br>
methylcellulose. The granules are dried, reduced to a<br>
suitable size, and mixed with stearic acid and magnesium<br>
stearate. The mixture is then compressed into individual<br>
tablets yielding a tablet weight of 240 mg.<br><br>
The mixture of raloxifene HCl, anhydrous lactose,<br>
hydrous spray-dried lactose, and a portion of the cross-<br>
linked polyvinylpyrrolidone is granulated with an aqueous<br>
solution of polyvinylpyrrolidone and polysorbate 80. The<br>
granules are dried, reduced to a suitable size, and mixed<br>
with magnesium stearate and the remaining cross-linked<br>
polyvinylpyrrolidone. The mixture is then compressed into<br>
individual tablets yielding a tablet weight of 230 mg.<br><br>
The mixture of raloxifene HCl, hydrous spray-dried<br>
lactose, and a portion of the cross-linked<br>
polyvinylpyrrolidone is granulated with an aqueous solution<br>
of polyvinylpyrrolidone and polysorbate 80. The granules<br>
are dried, reduced to a suitable size and mixed with<br>
magnesium stearate and remaining cross-linked<br>
polyvinylpyrrolidone. The mixture is then compressed into<br>
individual tablets yielding a tablet weight of 230 mg.<br><br>
The mixture of raloxifene HCl and anhydrous lactose is<br>
granulated with an aqueous solution of polysorbate 80 and<br>
poiyvinylpyrrolidone. The granules are dried, reduced to a<br>
suitable size, and mixed with the polyethylene glycol 8000.<br>
The mixture is then compressed into individual tablets<br>
yielding a tablet weight of 230 mg.<br>
Capsules may be prepared using the ingredients and<br>
procedures as described below:<br><br>
The mixture of raloxifene HCl, hydrous spray-dried<br>
lactose, and cross-linked poiyvinylpyrrolidone is<br>
granulated with an aqueous solution of sodium laurylsulfate<br>
and hydroxypropyl methylcellulose. The granules are dried,<br>
reduced to a suitable size, and mixed with colloidal<br>
silicon dioxide. This mixture is then filled into Size 3<br>
hard-shell gelatin capsules utilizing conventional<br>
encapsulating equipment, with each capsule containing 23 0<br>
mg of the final mixture.<br><br>
The mixture of raloxifene HCl, hydrous spray-dried<br>
lactose, and cross-linked polyvinylpyrrolidone is<br>
granulated with an aqueous solution of sodium laurylsulfate<br>
and hydroxypropyl methylcellulose. The granules are dried,<br>
reduced to a suitable size, and mixed with colloidal<br>
silicon dioxide. This mixture is then filled into Size 3<br>
hard-shell gelatin capsules utilizing conventional<br>
encapsulating equipment, with each capsule containing 23 0<br>
mg of the final mixture.<br><br>
The mixture of raloxifene HCl, hydrous spray-dried<br>
lactose, and cross-linked polyvinylpyrrolidone is<br>
granulated v/ith an aqueous solution of sodium laurylsulfate<br>
and hydroxypropyi methvlcellulose. The granules are dried,<br>
reduced to a suitable size, and mixed v/ith colloidal<br>
silicon dioxide. This mixture is then filled into Size 3<br>
hard-shell gelatin capsules utilizing conventional<br>
encapsulating equipment, with each capsule containing 230<br>
mg of the final mixture.<br>
We Claim:<br>
1. An orally administerable pharmaceutical formulation consisting essentially of<br>
raloxifene hydrochloride, in combination with a surfactant, polyvinylpyrrolidone and<br>
a water-soluble diluent, wherein:<br>
the surfactant is selected from the group consisting of sodium docusate, ethoxylated<br>
castor oil, polyglyucolysed glycerides, acetylated monoglycerides, sorbitan fatty acid<br>
esters, poloxamers. polyoxyethylene sorbitan fatty acid esters, polyoxyethylene<br>
derivatives, monoglycerides or ethoxylated derivatives threreof, and diglycerides or<br>
polyoxyethylene derivatives thereof; and<br>
the water-soluble diluent is a polyol or sugar,<br>
2. The formulation as claimed in claim 1, wherein the surfactant is a polyoxyethylene<br>
sorbitan fatty acid ester.<br>
3. The formulation as claimed in claim 1 or 2, wherein the surfactant is polysorbate 80.<br>
4. The formulation as claimed in claim 1 to 3, wherein the water-soluble diluent is a<br>
5. The formulation as claimed in any one of claims 1 to 4, wherein the water-soluble<br>
diluent is lactose.<br>
6. The formulation as claimed in any one of claims 1 to 5, further comprising a lubricant<br>
and a disintegrant.<br>
7. The formulation as claimed in claim 6, wherein the lubricant is magnesium stearate or<br>
stearic acid, and the disintegrant is cross-linked polyvinylpyrrolidone.<br>
8. An orally administerable pharmaceutical formulation consisting essentially of<br>
raloxifene hydrochloride in combination with polysorbate 80, cross-linked<br>
polyvinylpyrrolidone, lactose, polyvinylpyrrolidone and magnesium stearate.<br>
9. The formulation as claimed in any one of claims 1 to 8 further comprising a film<br>
coating.<br>
This invention provides orally administerable pharmaceutical<br>
formulations comprising raloxifene, its ethers or esters, or a<br>
pharmaceutically-acceptable salt thereof, in combination with a<br>
hydrophilic carrier composition.</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg0LUNBTC0xOTk1LSgxNC0wMi0yMDEyKS1GT1JNLTI3LnBkZg==" target="_blank" style="word-wrap:break-word;">184-CAL-1995-(14-02-2012)-FORM-27.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg0LUNBTC0xOTk1LSgxNC0wMi0yMDEyKS1GT1JNLTI3YS4ucGRm" target="_blank" style="word-wrap:break-word;">184-CAL-1995-(14-02-2012)-FORM-27a..pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg0LWNhbC0xOTk1LWdyYW50ZWQtYWJzdHJhY3QucGRm" target="_blank" style="word-wrap:break-word;">184-cal-1995-granted-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg0LWNhbC0xOTk1LWdyYW50ZWQtYXNzaWdubWVudC5wZGY=" target="_blank" style="word-wrap:break-word;">184-cal-1995-granted-assignment.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg0LWNhbC0xOTk1LWdyYW50ZWQtY2xhaW1zLnBkZg==" target="_blank" style="word-wrap:break-word;">184-cal-1995-granted-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg0LWNhbC0xOTk1LWdyYW50ZWQtY29ycmVzcG9uZGVuY2UucGRm" target="_blank" style="word-wrap:break-word;">184-cal-1995-granted-correspondence.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg0LWNhbC0xOTk1LWdyYW50ZWQtZGVzY3JpcHRpb24gKGNvbXBsZXRlKS5wZGY=" target="_blank" style="word-wrap:break-word;">184-cal-1995-granted-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg0LWNhbC0xOTk1LWdyYW50ZWQtZXhhbWluYXRpb24gcmVwb3J0LnBkZg==" target="_blank" style="word-wrap:break-word;">184-cal-1995-granted-examination report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg0LWNhbC0xOTk1LWdyYW50ZWQtZm9ybSAxLnBkZg==" target="_blank" style="word-wrap:break-word;">184-cal-1995-granted-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg0LWNhbC0xOTk1LWdyYW50ZWQtZm9ybSAxMy5wZGY=" target="_blank" style="word-wrap:break-word;">184-cal-1995-granted-form 13.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg0LWNhbC0xOTk1LWdyYW50ZWQtZm9ybSAxOC5wZGY=" target="_blank" style="word-wrap:break-word;">184-cal-1995-granted-form 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg0LWNhbC0xOTk1LWdyYW50ZWQtZm9ybSAyLnBkZg==" target="_blank" style="word-wrap:break-word;">184-cal-1995-granted-form 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg0LWNhbC0xOTk1LWdyYW50ZWQtZm9ybSAyNi5wZGY=" target="_blank" style="word-wrap:break-word;">184-cal-1995-granted-form 26.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg0LWNhbC0xOTk1LWdyYW50ZWQtZm9ybSAzLnBkZg==" target="_blank" style="word-wrap:break-word;">184-cal-1995-granted-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg0LWNhbC0xOTk1LWdyYW50ZWQtZm9ybSA1LnBkZg==" target="_blank" style="word-wrap:break-word;">184-cal-1995-granted-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg0LWNhbC0xOTk1LWdyYW50ZWQtcmVwbHkgdG8gZXhhbWluYXRpb24gcmVwb3J0LnBkZg==" target="_blank" style="word-wrap:break-word;">184-cal-1995-granted-reply to examination report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTg0LWNhbC0xOTk1LWdyYW50ZWQtc3BlY2lmaWNhdGlvbi5wZGY=" target="_blank" style="word-wrap:break-word;">184-cal-1995-granted-specification.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="224746-antagonistic-peptides-of-prostaglandin-e2-receptor-subtype-ep4.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="224748-novel-anticonvulsant-derivative-salts.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>224747</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>184/CAL/1995</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>43/2008</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>24-Oct-2008</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>22-Oct-2008</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>23-Feb-1995</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>ELI LILLY AND COMPANY</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>LILLY CORPORATE CENTER, CITY OF INDIANAPOLIS, STATE OF INDIANA</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>LOWELL LEE, GIBSON</td>
											<td>4184 MESSERSMITH DR., GREENWOOD, INDIANA 46142</td>
										</tr>
										<tr>
											<td>2</td>
											<td>KERRY JOHN, HARTAUER</td>
											<td>6306 ECHO CT., INDIANAPOLIS, INDIANA 46278</td>
										</tr>
										<tr>
											<td>3</td>
											<td>JULIAN LARRY, STOWERS</td>
											<td>7325 LANTERN ROAD, INDIANAPOLIS, INDIANA 46256</td>
										</tr>
										<tr>
											<td>4</td>
											<td>STEPHANIE ANN, SWEETANA</td>
											<td>4112 SARATOGA DR., BLOOMINGTON, INDIANA 47401</td>
										</tr>
										<tr>
											<td>5</td>
											<td>ARVIND LAVJI, THAKKAR</td>
											<td>9020 YELLOWWOOD COURT, INDIANAPOLIS, INDIANA 46260</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K 9/20, 31/445</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>N/A</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td></td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td></td>
									<td></td>
								    <td>NA</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/224747-a-pharmaceutical-composition-comprising-raloxifene-a-surfactant-and-a-watersoluble-diluent by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 00:59:18 GMT -->
</html>
